Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet Haematology; 20240101, Issue: Preprints
- Subject
- Language
- ISSN
- 23523026